Udai S Kammula

University Of Pittsburgh At Pittsburgh

$3,268,624

Attributed

$3,268,624

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $607.5K · FY2019–25

$1M$750K$500K$250K$0

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$3,268,624 · 2

By mechanism

R01$1,775,650 · 1

T32$1,492,974 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

John Munn Kirkwood$15,450,309
Radosveta P Koldamova$12,908,953
Iliya Lefterov$9,615,606
Rajiv Dhir$8,351,145
Michael T Lotze$5,139,928

Others in their field

Other Emerging Leaders on “Malignant Neoplasms”

Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
Martha Hering · Westat, Inc.$57,098,843

Research focus

Malignant NeoplasmsResearch TrainingBiological Response Modifier TherapyAdoptive ImmunotherapyApoptosisArg2 GeneAntigensAutologous Tumor-Infiltrating LymphocyteAutomobile DrivingBioenergeticsClinically RelevantBiomedical EngineeringCancer ImmunotherapyCancer PatientCell DeathCd8b1 GeneCell PhysiologyCellsCell TypeCellular Metabolic ProcessChromatin ImmunoprecipitationChronicAutologousAdoptive Transfer